Nadine A. Friedrich

Jul 19, 2024 | onlinelibrary.wiley.com | Nadine A. Friedrich |Lin Gu |Justin Waller |Zachary Klaassen

CONFLICT OF INTEREST STATEMENT Stephen J. Freedland, MD, is a consultant for Myovant, Pfizer, Astellas, Bayer, Janssen, Sanori, Merck, and Astra Zeneca. The remaining authors declare no conflict of interest. REFERENCES 1, , , et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1): 56-63. 2, , , et al.

Feb 22, 2024 | nature.com | Timothy J. Daskivich |Aurash Naser-Tavakolian |Nadine A. Friedrich |Howard M. Sandler

AbstractEffective communication of treatment side effects (SE) is critical for shared decision-making (SDM) in localized prostate cancer. We sought to qualitatively characterize how physicians communicate SE in consultations. We transcribed 50 initial prostate cancer treatment consultations across nine multidisciplinary providers (Urologists, Radiation Oncologists, Medical Oncologists) at our tertiary referral, academic center.